ESSA PHARMA INC (EPIX)

CA29668H7085 - Common Stock

1.76  +0.03 (+1.73%)

News Image
3 days ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are...

News Image
16 days ago - Chartmill

Which stocks have an unusual volume on Tuesday?

Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

News Image
17 days ago - Chartmill

In today's session, these stocks are experiencing unusual volume.

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

News Image
20 days ago - Chartmill

These stocks are moving in today's after hours session

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

News Image
21 days ago - ESSA Pharma Inc

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to...

News Image
2 months ago - ESSA Pharma Inc

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...

News Image
2 months ago - ESSA Pharma Inc

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...

News Image
2 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment...

News Image
2 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

/PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

News Image
4 months ago - ESSA Pharma Inc

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the...

News Image
4 months ago - ESSA Pharma Inc

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the...

News Image
5 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the JonesHealthcare Seaside Summit

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

News Image
5 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the JonesHealthcare Seaside Summit

/PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

News Image
5 months ago - Market News Video

Relative Strength Alert For ESSA Pharma

News Image
6 months ago - Market News Video

EPIX Crosses Below Key Moving Average Level

News Image
6 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

News Image
6 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

News Image
6 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday!

News Image
6 months ago - InvestorPlace

EPIX Stock Earnings: ESSA Pharma Misses EPS for Q2 2024

EPIX stock results show that ESSA Pharma missed analyst estimates for earnings per share the second quarter of 2024.

News Image
6 months ago - ESSA Pharma Inc

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...

News Image
6 months ago - ESSA Pharma Inc

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...

News Image
6 months ago - Market News Video

ESSA Pharma is Now Oversold (EPIX)

News Image
8 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

News Image
8 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

News Image
8 months ago - Market News Video

Oversold Conditions For ESSA Pharma (EPIX)

News Image
9 months ago - ESSA Pharma Inc

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...

News Image
9 months ago - ESSA Pharma Inc

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

/PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...

News Image
9 months ago - ESSA Pharma Inc

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

News Image
10 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

News Image
10 months ago - ESSA Pharma Inc

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...

News Image
10 months ago - ESSA Pharma Inc

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose...